Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
Observational Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
Sponsor: Assistance Publique Hopitaux De Marseille
Listed as NCT04003922, this observational or N/A phase trial focuses on Rasmussen Encephalitis and remains ongoing. Sponsored by Assistance Publique Hopitaux De Marseille, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
-
May 2023 — Feb 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Sep 2022 — May 2023 [monthly]
Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting
-
Aug 2019 — Jan 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique Hopitaux De Marseille
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Brest, France , Lille, France , Limoges, France , Lyon, France , Marseille, France , Montpellier, France , Nancy, France , Paris, France , Rennes, France and 3 more locations